AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

IOVA · NASDAQ · Biotechnology

Iovance Biotherapeutics

Commercializes TIL cell therapies for melanoma and other solid-tumor settings.

$8.03

After-hours close+0.00 (+0.06%)

At close$8.03(−2.85%)

Something off on this page? Send us feedback.

Profile

Iovance Biotherapeutics, Inc.IOVAHealth Care

Sells Amtagvi and Proleukin, pairing an FDA-approved TIL cell therapy with the interleukin-2 product used in treatment and manufacturing. Operations center on oncology access, cell-therapy manufacturing, authorized treatment centers, and confirmatory evidence required under accelerated approval.

Markets Amtagvi, a lifileucel TIL cell therapy for previously treated unresectable or metastatic melanoma, alongside Proleukin, the aldesleukin product used in the Amtagvi regimen and sold for other oncology, manufacturing, clinical, and research uses.

Commercial work is centered in U.S. oncology channels, with Canadian conditional authorization extending the same core melanoma therapy into another regulated market. Manufacturing is built around the Iovance Cell Therapy Center in Philadelphia, nearby contract capacity, and authorized treatment centers that collect and ship tumor tissue.

Execution depends on patient access, reliable cell-therapy manufacturing, Proleukin supply and use, and confirmatory evidence required by the accelerated-approval pathway. Promotional materials also operate under FDA scrutiny after the agency challenged exploratory overall-survival claims.

Company facts

CEOFrederick G. Vogt

ListedJun 28, 2017

ExchangeNASDAQ

HeadquartersSan Carlos, CA

CountryUnited States

Employees975

CIK0001425205

ISINUS4622601007

Key statistics

Market cap$3.58B

EPS (ttm)−$0.7000

P/E (ttm)−11.44

ROE-40.5%

P/B4.90

P/S11.01

Dividend yield—

Beta1.32vs XLV 1.08

Year to date +218% · Average volume (30d) 17.7M

Analysts

Price target, next 12 months$6.50−18.9%Median of 21 analysts · vs the Aug 28 close

ConsensusBuy16 of 21 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $8.01

High$13.00+62.3%

Median$6.50−18.9%

Low$5.00−37.6%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 20, 2026	UBS	Reiterate	Neutral	$2	$7
Aug 18, 2026	Mizuho Securities	Target			$11
Aug 7, 2026	Robert W. Baird	Target		$24	$6
Aug 7, 2026	Barclays	Reiterate	Overweight	$40	$13
Jun 1, 2026	National Bank	Target			$5

Earnings

EPS

Estimate−$0.12

ReportedDue Nov 5, 2026

Revenue

Estimate$110.1M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	−$0.13	−$0.11	+17.6%	$87.8M	$99.3M	+13.1%	+43.09%
May 7, 2026Q1 FY26	−$0.19	−$0.19	0.0%	$77.8M	$71.4M	−8.2%	+1.97%
Feb 24, 2026Q4 FY25	−$0.22	−$0.18	+18.2%	$80.7M	$86.7M	+7.4%	+1.32%
Nov 6, 2025Q3 FY25	−$0.29	−$0.25	+13.8%	$82.2M	$67.5M	−17.9%	−0.43%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$49.3M	$60.0M	$67.5M	$86.8M	$71.4M	$99.3M
Gross profit	−$417.0K	$3.3M	$66.0M	$187.3M	$70.4M	$54.2M
Operating income	−$121.2M	−$113.8M	−$94.9M	−$73.5M	−$81.0M	−$51.9M
Net income	−$116.2M	−$111.7M	−$91.3M	−$71.9M	−$79.0M	−$47.3M
Diluted EPS	−$0.36	−$0.33	−$0.25	−$0.15	−$0.19	−$0.11
Gross margin	-0.8%	5.5%	97.9%	215.9%	98.6%	54.6%
Operating margin	-245.8%	-189.8%	-140.7%	-84.7%	-113.5%	-52.3%

Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $1.2M · FY24 $164.1M · FY25 $263.5M

Revenue by geography · Q2 FY26

United States$99.0M · 100%

Non-US$346.0K · 0%

Balance sheet, Jun 30, 2026Cash & short-term investments $297.7M · Total debt $46.0M · Total assets $915.5M · Shareholders' equity $736.0M

Dividends

No dividends on record.

Ownership

Institutions 60.27%269.11M sharesInsiders 0.32%1.42M sharesOther 39.41%175.98M shares

Shares outstanding 446.50M · Float 387.87M · 86.9% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	31.08M	6.96%	13F	May 13, 2026
MHR Fund Management LLC	28.97M	6.49%	13F	May 15, 2026
State Street Corporation	24.48M	5.50%	13G	Aug 7, 2026
Vanguard Capital Management LLC	16.62M	3.72%	13F	May 15, 2026
Two Sigma Investments, LP	13.69M	3.07%	13F	May 15, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.